Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Burkina Faso forces killed twice as many civilians as jihadists, rights group says - 2Father and son spending Christmas together after health scares
- 3Was This Driver Simply Having A great time Or Behaving Like An Ass?
- 4Council removes proposal to rename park named after former president of Israel
- 55 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Becoming amazing at Systems administration: Individual and Expert Tips
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Germany sees third consecutive diesel price record after rule change
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- Five EU states press for windfall taxes on fossil energy sector
